Background/Objectives: Information on the economic impact and healthcare resource utilization (HCRU) associated with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is lacking. Methods: A retrospective review of medical records identified patients diagnosed with BPDCN between 2009 and 2023. Data on outpatient resource use, reimbursement, frequency and duration of hospitalizations, and transfusion burden were collected from diagnosis to death or last follow-up. Results: A total of 38 patients with a median age of 66 years were included. Conventional intensive chemotherapy (CHT) regimens were initially administered to 58% of patients, while targeted therapies were used in 37% of cases. The ratio of total days hospitalized to the overall follow-up period was 17%, with a total of 182 hospitalizations (average of 5 per patient; mean duration 20 days). The mean total reimbursement was EUR 109,104 per patient, primarily attributed to hospital admissions (EUR 89,158; EUR 18,118 per hospitalization). Hospitalizations before or without any allogeneic hematopoietic stem cell transplant (alloHSCT) accounted for 70% of total admissions, with an average overall cost of EUR 50,285 per patient (EUR 12,427 per hospitalization). AlloHSCT-period hospitalizations occurred in 18 patients, with a mean total reimbursement of EUR 122,497 per patient and EUR 30,464 per hospitalization. Conclusions: The active treatment of BPDCN imposes a high economic burden and extensive HCRU. Comparative pharmacoeconomic studies evaluating the cost-effectiveness of new therapies for BPDCN are needed to identify patient subgroups that may benefit most from these treatments.
背景/目的：目前关于母细胞性浆细胞样树突细胞肿瘤（BPDCN）相关经济影响及医疗资源利用（HCRU）的数据尚不充分。方法：通过回顾性分析医疗记录，识别2009年至2023年间诊断为BPDCN的患者。收集从确诊至死亡或末次随访期间的门诊资源使用、医疗费用报销、住院频率与时长以及输血负荷等数据。结果：共纳入38例患者，中位年龄66岁。58%的患者初始接受常规强化化疗方案，37%接受靶向治疗。住院总天数占整体随访时长的比例为17%，累计住院182次（人均5次；平均住院时长20天）。患者人均总报销费用为109,104欧元，主要源于住院费用（89,158欧元；单次住院平均费用18,118欧元）。异基因造血干细胞移植（alloHSCT）前或未接受移植期间的住院次数占总住院次数的70%，患者人均总费用为50,285欧元（单次住院平均费用12,427欧元）。18例患者在接受alloHSCT期间发生住院，人均总报销费用为122,497欧元，单次住院平均费用为30,464欧元。结论：BPDCN的积极治疗带来较高的经济负担和广泛的医疗资源消耗。未来需开展药物经济学比较研究，评估BPDCN新疗法的成本效益，以明确可能从中获益最大的患者亚群。
肿瘤(癌症)患者之家